Evidence map›Paper›PMID 32915522›Full record

ArticleJournal of biomedical materials research. Part B, Applied biomaterials2021

Regeneration enhanced in critical-sized bone defects using bone-specific extracellular matrix protein.

Solaleh Miar, Joseph Pearson, Sergio Montelongo, Rogelio Zamilpa, Alejandro M Betancourt, Bharath Ram, Christopher Navara, Mark R Appleford, Joo L Ong, Sy Griffey and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of biomedical materials research. Part B, Applied biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Solaleh MiarDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Joseph PearsonDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Sergio MontelongoDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Rogelio ZamilpaStemBioSys Inc., San Antonio, Texas, USA.
Alejandro M BetancourtDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Bharath RamDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Christopher NavaraDepartment of Biology, University of Texas at San Antonio, San Antonio, Texas, USA.
Mark R ApplefordDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Joo L OngDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Sy GriffeyStemBioSys Inc., San Antonio, Texas, USA.
Teja GudaDepartment of Biomedical Engineering and Chemical Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-3218-2916
The University of Texas at San Antonio · USTargazyme (United States) · US

Funding

UTSA RISE Research Training ProgramR25GM060655 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 2000 to 2022
$21.6M
UTSA Maximizing Access to Research Careers Research Training Program - Admin SupplementT34GM007717 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 1985 to 2021
$9.5M
NIGMS NIH HHS R25 GM060655NIGMS NIH HHS T34 GM007717
6 · The paper itself

Abstract

Extracellular matrix (ECM) products have the potential to improve cellular attachment and promote tissue-specific development by mimicking the native cellular niche. In this study, the therapeutic efficacy of an ECM substratum produced by bone marrow stem cells (BM-MSCs) to promote bone regeneration in vitro and in vivo were evaluated. Fluorescence-activated cell sorting analysis and phenotypic expression were employed to characterize the in vitro BM-MSC response to bone marrow specific ECM (BM-ECM). BM-ECM encouraged cell proliferation and stemness maintenance. The efficacy of BM-ECM as an adjuvant in promoting bone regeneration was evaluated in an orthotopic, segmental critical-sized bone defect in the rat femur over 8 weeks. The groups evaluated were either untreated (negative control); packed with calcium phosphate granules or granules+BM-ECM free protein and stabilized by collagenous membrane. Bone regeneration in vivo was analyzed using microcomputed tomography and histology. in vivo results demonstrated improvements in mineralization, osteogenesis, and tissue infiltration (114 ± 15% increase) in the BM-ECM complex group from 4 to 8 weeks compared to mineral granules only (45 ± 21% increase). Histological observations suggested direct apposition of early bone after 4 weeks and mineral consolidation after 8 weeks implantation for the group supplemented with BM-ECM. Significant osteoid formation and greater functional bone formation (polar moment of inertia was 71 ± 0.2 mm

Indexed as

AnimalsBone RegenerationCalcification, PhysiologicCalcium PhosphatesCollagenExtracellular Matrix ProteinsFemurIn Vitro TechniquesMaterials TestingMesenchymal Stem CellsOrgan SpecificityOsteogenesisRatsRats, Sprague-DawleyX-Ray Microtomographycalcium phosphateCalcium PhosphatesCollagenExtracellular Matrix Proteins

Identifiers

PMID32915522
PMCPMC8740960
OpenAlexW3086100869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.